Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The function of COX-2 in human ovarian carcinoma.

× No keyword cloud information.

9 in total

1. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives.

Authors: E E Voest; J C van Houwelingen; J P Neijt
Journal: Eur J Cancer Clin Oncol Date: 1989-04

2. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.

Authors: K Bertelsen
Journal: Gynecol Oncol Date: 1990-08 Impact factor: 5.482

3. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors: Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544

4. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

Authors: Carsten Denkert; Martin Köbel; Sören Pest; Ines Koch; Stefan Berger; Michael Schwabe; Antje Siegert; Angela Reles; Bernd Klosterhalfen; Steffen Hauptmann
Journal: Am J Pathol Date: 2002-03 Impact factor: 4.307

5. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.

Authors: M S Piver; S B Lele; D L Marchetti; T R Baker; Y Tsukada; L J Emrich
Journal: J Clin Oncol Date: 1988-06 Impact factor: 44.544

6. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

Authors: R W Hunter; N D Alexander; W P Soutter
Journal: Am J Obstet Gynecol Date: 1992-02 Impact factor: 8.661

7. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.

Authors: W J Hoskins; B N Bundy; J T Thigpen; G A Omura
Journal: Gynecol Oncol Date: 1992-11 Impact factor: 5.482

8. Cyclooxygenase-2 (COX-2) a new prognostic and predictive factor for ovarian cancer? Are all the criteria fulfilled?

Authors: M L Nasi; M Castiglione
Journal: Ann Oncol Date: 2002-08 Impact factor: 32.976

9. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients.

Authors: G Ferrandina; L Lauriola; G F Zannoni; A Fagotti; F Fanfani; F Legge; N Maggiano; M Gessi; S Mancuso; F O Ranelletti; G Scambia
Journal: Ann Oncol Date: 2002-08 Impact factor: 32.976

9 in total